SIG
GRCE

Sargent Investment Group’s Grace Therapeutics GRCE Stock Holding History

Sargent Investment Group’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-349
Closed -$3K – 199
2020
Q3 		$3K Sell
349
-636
-65% -$16.5K ﹤0.01% 165
2020
Q2 		$25K Hold
985
– – 0.01% 147
2020
Q1 		$18K Sell
985
-324
-25% -$11.5K 0.01% 136
2019
Q4 		$154K Buy
+1,309
New +$129K 0.06% 148

Other funds holding GRCE

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MMPW
Mitchell McLeod Pugh & Williams Mobile, Alabama $678M AUM 23.02% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sargent Investment Group's GRCE Position: Q4 2020 in Review

Sargent Investment Group sold out of Grace Therapeutics (GRCE) in Q4 2020, closing a stake of 349 shares — an estimated $3K sold.

Sargent Investment Group first reported a position in GRCE in Q4 2019 and held it in 4 quarters. The position peaked at $154K in Q4 2019. 28 funds tracked by Wall St. Rank hold GRCE as of Q4 2020.

  • Sargent Investment Group reported no remaining Grace Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Sargent Investment Group sold 349 Grace Therapeutics shares in Q4 2020, an estimated $3K.
  • Sargent Investment Group first reported a position in Grace Therapeutics in Q4 2019 and held it in 4 quarters.
  • Sargent Investment Group's Grace Therapeutics position peaked at $154K in Q4 2019.
  • 28 funds tracked by Wall St. Rank held Grace Therapeutics as of Q4 2020.

Based on Sargent Investment Group's 13F filing for Q4 2020, filed 10 Feb 2021.